t(9;22)(q34;q11) BCR/ABL1 in treatment related leukemia
2003-10-01 Jean-Loup Huret Affiliation1.Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France
Clinics and Pathology
Disease
Treatment related acute myeloid leukaemias (t-AML) and lymphocytic leukemias (t-ALL)
Note
The study included 10 cases; t-AML and t-ALL accounted for half cases each. Treatment related acute lymphocytic leukemias (t-ALL) are extremely rare, found in only 20 of 511 cases (4%) in this workshop: 5 cases of t(9;22), 12 cases of t(4;11)(q22;q23), 2 cases of t(8;14)(q24;q32), and 1 case of t(11;19)(q23;p13.3)
Epidemiology
t(9;22)(q34;q11) was found in 2% of treatment related acute leukaemias; sex ratio: 2M/8F
Clinics
Age at diagnosis of the primary disease 45 yrs (range 3-76); age at diagnosis of the t-MDS/t-AML: 64 yrs (range 12-78). Median interval was long: 110 mths (range: 25-310). Primary disease was a solid tumor in 70% of cases (in particular breast cancer) and a hematologic malignancy in 20%; treatment was radiotherapy in 1/10, chemotherapy (6/10), or both (3/10). Treatment included topoisomerase II inhibitors in 4 of 9 cases and alkylating agents in 5/9.
Prognosis
Median survival was very poor: 5 mths, with 14% of patients surviving at 1 yr, and none at 2 yrs.
Genes Involved and Proteins
Highly cited references
| Pubmed ID | Year | Title | Citations |
|---|---|---|---|
| 35057108 | 2022 | BCR-ABL1 Tyrosine Kinase Complex Signaling Transduction: Challenges to Overcome Resistance in Chronic Myeloid Leukemia. | 188 |
| 18827185 | 2009 | Molecular biology of bcr-abl1-positive chronic myeloid leukemia. | 137 |
| 35884363 | 2022 | Mechanisms of Resistance and Implications for Treatment Strategies in Chronic Myeloid Leukaemia. | 123 |
| 28804122 | 2018 | SHP2 is required for BCR-ABL1-induced hematologic neoplasia. | 99 |
| 37337105 | 2023 | Transcriptomic classes of BCR-ABL1 lymphoblastic leukemia. | 91 |
| 38550948 | 2023 | Targeting BCR-ABL1-positive leukaemias: a review article. | 88 |
| 38653245 | 2024 | Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemia. | 83 |
| 37629188 | 2023 | Diagnosis- and Prognosis-Related Gene Alterations in BCR::ABL1-Negative Myeloproliferative Neoplasms. | 80 |
| 39098922 | 2024 | BCR::ABL1 Proteolysis-targeting chimeras (PROTACs): The new frontier in the treatment of Ph(+) leukemias? | 75 |
| 38457494 | 2024 | ERG and c-MYC regulate a critical gene network in BCR::ABL1-driven B cell acute lymphoblastic leukemia. | 73 |
| 38397221 | 2024 | Frequencies of BCR::ABL1 Transcripts in Patients with Chronic Myeloid Leukemia: A Meta-Analysis. | 67 |
| 37373266 | 2023 | Molecular BCR::ABL1 Quantification and ABL1 Mutation Detection as Essential Tools for the Clinical Management of Chronic Myeloid Leukemia Patients: Results from a Brazilian Single-Center Study. | 66 |
| 27366312 | 2016 | New Developments in Chronic Myeloid Leukemia: Implications for Therapy. | 65 |
| 33194157 | 2020 | NPM1 Mutated, BCR-ABL1 Positive Myeloid Neoplasms: Review of the Literature. | 64 |
| 29022901 | 2017 | BCR-ABL1-induced downregulation of WASP in chronic myeloid leukemia involves epigenetic modification and contributes to malignancy. | 63 |
| 34276365 | 2021 | Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts. | 62 |
| 37386079 | 2023 | MEK1/2 regulate normal BCR and ABL1 tumor-suppressor functions to dictate ATO response in TKI-resistant Ph+ leukemia. | 61 |
| 38282677 | 2023 | Co-occurrence of JAK2-V617 F mutation and BCR::ABL1 translocation in chronic myeloproliferative neoplasms: a potentially confounding genetic combination. | 60 |
| 33283168 | 2020 | Digital PCR for BCR-ABL1 Quantification in CML: Current Applications in Clinical Practice. | 58 |
| 37161070 | 2023 | Mast cell deficiency prevents BCR::ABL1 induced splenomegaly and cytokine elevation in a CML mouse model. | 58 |
| 32154668 | 2020 | Next-generation sequencing for BCR-ABL1 kinase domain mutations in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position paper. | 53 |
| 33949040 | 2021 | RAG enhances BCR-ABL1-positive leukemic cell growth through its endonuclease activity in vitro and in vivo. | 53 |
| 35551463 | 2022 | BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro. | 51 |
| 38386975 | 2024 | Tyrosine kinase inhibitor resistance in de novo BCR::ABL1-positive BCP-ALL beyond kinase domain mutations. | 51 |
| 39652455 | 2025 | BCR::ABL1-induced mitochondrial morphological alterations as a potential clinical biomarker in chronic myeloid leukemia. | 51 |
| 31289206 | 2020 | Human BCR/ABL1 induces chronic myeloid leukemia-like disease in zebrafish. | 49 |
| 26291129 | 2015 | MAPK15 mediates BCR-ABL1-induced autophagy and regulates oncogene-dependent cell proliferation and tumor formation. | 47 |
| 26179066 | 2015 | BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene. | 46 |
| 37875583 | 2023 | Continuous therapy response references for BCR::ABL1 monitoring in pediatric chronic myeloid leukemia. | 44 |
| 31311809 | 2019 | Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-Mediated Targeted Protein Degradation. | 42 |
| 39440695 | 2024 | New ABL1 Kinase Domain Mutations in BCR::ABL1-Positive Acute Lymphoblastic Leukemia. | 42 |
| 34902205 | 2022 | RUNX1 transactivates BCR-ABL1 expression in Philadelphia chromosome positive acute lymphoblastic leukemia. | 42 |
| 35816360 | 2022 | Inflammation accelerates BCR-ABL1+ B-ALL development through upregulation of AID. | 41 |
| 37400842 | 2023 | BCR::ABL1-like acute lymphoblastic leukaemia: a single institution experience on identification of potentially therapeutic targetable cases. | 41 |
| 31543464 | 2019 | Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants. | 40 |
| 37165001 | 2023 | Targeting Poly(ADP)ribose polymerase in BCR/ABL1-positive cells. | 40 |
| 37807980 | 2023 | High BCR::ABL1 Expression Defines CD34+ Cells with Significant Alterations in Signal Transduction, Short-Proliferative Potential and Self-Renewal Ability. | 39 |
| 38596359 | 2024 | Chronic myeloproliferative neoplasms with concomitant CALR mutation and BCR::ABL1 translocation: diagnostic and therapeutic implications of a rare hybrid disease. | 38 |
| 21299849 | 2011 | BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance. | 38 |
| 31456947 | 2019 | BCR-ABL1 Doubling-Times and Halving-Times May Predict CML Response to Tyrosine Kinase Inhibitors. | 37 |
| 38395895 | 2024 | Pharmacovigilance study of BCR-ABL1 tyrosine kinase inhibitors: a safety analysis of the FDA adverse event reporting system. | 36 |
| 27611742 | 2016 | Novel BCR-ABL1 fusion and leukemic mutations of SETBP1, PAX5, and TP53 detected by next generation sequencing in chronic myeloid leukemia. | 36 |
| 28533818 | 2017 | A novel BCR-ABL1 fusion gene with genetic heterogeneity indicates a good prognosis in a chronic myeloid leukemia case. | 33 |
| 36086954 | 2023 | Targeting the PTP1B-Bcr-Abl1 interaction for the degradation of T315I mutant Bcr-Abl1 in chronic myeloid leukemia. | 32 |
| 34771634 | 2021 | Droplet Digital PCR for BCR-ABL1 Monitoring in Diagnostic Routine: Ready to Start? | 31 |
| 29976745 | 2018 | BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia. | 28 |
| 38153913 | 2024 | Developmental trajectories and cooperating genomic events define molecular subtypes of BCR::ABL1-positive ALL. | 23 |
| 38821940 | 2024 | Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. A DATAML registry study. | 22 |
| 36195570 | 2023 | Hypoxia-inducible factor 1α inhibitor induces cell death via suppression of BCR-ABL1 and Met expression in BCR-ABL1 tyrosine kinase inhibitor sensitive and resistant chronic myeloid leukemia cells. | 22 |
| 37496024 | 2023 | FISH-negative BCR::ABL1-positive e19a2 chronic myeloid leukaemia: the most cryptic of insertions. | 21 |
| 32127950 | 2020 | BCR-ABL1 transcript decline ratio combined BCR-ABL1(IS) as a precise predictor for imatinib response and outcome in the patients with chronic myeloid leukemia. | 21 |
| 33814500 | 2021 | BCR/ABL1-positive B-lymphoblastic Lymphoma Successfully Treated with Dasatinib-combined Chemotherapy. | 20 |
| 38906962 | 2024 | Asciminib antagonizes transplantable BCR::ABL1-positive lymphoid blast crisis in vivo by targeting malignant stem cells. | 20 |
| 30125955 | 2018 | Consensus on BCR-ABL1 reporting in chronic myeloid leukaemia in the UK. | 19 |
| 35756686 | 2022 | Successful Preservation of Native BCR::ABL1 in Chronic Myeloid Leukemia Primary Leukocytes Reveals a Reduced Kinase Activity. | 18 |
| 25880391 | 2015 | Clonal distribution of BCR-ABL1 mutations and splice isoforms by single-molecule long-read RNA sequencing. | 17 |
| 31644323 | 2020 | BCR-ABL1-like B-Acute Lymphoblastic Leukemia/Lymphoma: A Comprehensive Review. | 0 |
| 35021069 | 2022 | Development of asciminib, a novel allosteric inhibitor of BCR-ABL1. | 0 |
| 33096322 | 2020 | The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase. | 0 |
| 38643492 | 2024 | BCR::ABL1 kinase N-lobe mutants confer moderate to high degrees of resistance to asciminib. | 0 |
| 37183966 | 2023 | Ultrasensitive NGS MRD assessment in Ph+ ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1. | 0 |
| 38394774 | 2024 | Beyond BCR::ABL1-The Role of Genomic Analyses in the Management of CML. | 0 |
| 39028928 | 2024 | Significance of Measurable Residual Disease in Adult Philadelphia Chromosome-Positive ALL: A GRAAPH-2014 Study. | 0 |
| 33038988 | 2020 | CML - Not only BCR-ABL1 matters. | 0 |
| 34818644 | 2022 | BCR/ABL1-Like Acute Lymphoblastic Leukemia: From Diagnostic Approaches to Molecularly Targeted Therapy. | 0 |
| 29696694 | 2018 | Laboratory testing in BCR-ABL1-like (Philadelphia-like) B-lymphoblastic leukemia/lymphoma. | 0 |
| 28222016 | 2017 | A review of the challenge in measuring and standardizing BCR-ABL1. | 0 |
| 31069976 | 2019 | BCR-ABL1-like B-lymphoblastic leukemia/lymphoma: Review of the entity and detection methodologies. | 0 |
| 30561755 | 2019 | BCR/ABL1-like acute lymphoblastic leukemia: How to diagnose and treat? | 0 |
| 27904889 | 2017 | Reactive oxygen species in BCR-ABL1-expressing cells - relevance to chronic myeloid leukemia. | 0 |
| 35609336 | 2022 | The Dawn of Allosteric BCR-ABL1 Drugs: From a Phenotypic Screening Hit to an Approved Drug. | 0 |
| 31696382 | 2019 | The Hidden Pathogenesis of CML: Is BCR-ABL1 the First Event? | 0 |
| 26297264 | 2015 | Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia. | 0 |
| 24407376 | 2014 | Genetic events other than BCR-ABL1. | 0 |
| 24131888 | 2014 | Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia. | 0 |
| 19002192 | 2008 | BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative disorders: some common and contrasting features. | 0 |
| 27412040 | 2017 | Measurement of BCR-ABL1 transcripts on the International Scale in the United States: current status and best practices. | 0 |
| 38734786 | 2024 | TIF1β activates leukemic transcriptional program in HSCs and promotes BCR::ABL1-induced myeloid leukemia. | 0 |
| 35171727 | 2022 | MUC4 expression by immunohistochemistry is a specific marker for BCR-ABL1+ and BCR-ABL1-like B-lymphoblastic leukemia. | 0 |
| 27131622 | 2016 | Early BCR-ABL1 Reduction Is Predictive of Better Event-free Survival in Patients With Newly Diagnosed Chronic Myeloid Leukemia Treated With Any Tyrosine Kinase Inhibitor. | 0 |
| 37479951 | 2023 | Mitochondrial Dysfunction in Cardiotoxicity Induced by BCR-ABL1 Tyrosine Kinase Inhibitors -Underlying Mechanisms, Detection, Potential Therapies. | 0 |
| 28035733 | 2017 | Frequency of rare BCR-ABL1 fusion transcripts in chronic myeloid leukemia patients. | 0 |
| 34185393 | 2021 | BCR-ABL1 p210 screening for chronic myeloid leukemia in patients with peripheral blood cytoses. | 0 |
| 37302352 | 2023 | Genetic alterations in the BCR-ABL1 fusion gene related to imatinib resistance in chronic myeloid leukemia. | 0 |
| 37078896 | 2023 | Management of chronic myeloid leukaemia: current treatment options, challenges, and future strategies. | 0 |
| 39217000 | 2025 | SOHO State of the Art Updates and Next Questions | Approach to BCR::ABL1-Like Acute Lymphoblastic Leukemia. | 0 |
| 28331056 | 2017 | Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology. | 0 |
| 34506622 | 2022 | Sequential Development of JAK2V617F Mutation and BCR-ABL1 Fusion in Individual Patients With Myeloproliferative Neoplasms. | 0 |
| 39291932 | 2024 | Low-Level BCR::ABL1 Transcript at Diagnosis in Childhood Leukemia: A 10-Year Single Institution Study. | 0 |
| 24367893 | 2014 | Sensitivity of SNX2-ABL1 toward tyrosine kinase inhibitors distinct from that of BCR-ABL1. | 0 |
| 39374639 | 2025 | New practice of BCR::ABL1 standardization system based on p210 and p190 BCR::ABL1 reference materials. | 0 |
| 25814077 | 2015 | Natural course and biology of CML. | 0 |
| 39167824 | 2024 | Comparative analysis of BCR::ABL1 p210 mRNA transcript quantification and ratio to ABL1 control gene converted to the International Scale by chip digital PCR and droplet digital PCR for monitoring patients with chronic myeloid leukemia. | 0 |
| 31707540 | 2020 | Low prevalence of the BCR-ABL1 fusion gene in a normal population in southern Sarawak. | 0 |
| 39743410 | 2024 | A Review of Clonal Relationships in Myeloproliferative Neoplasms With Co-Mutations of JAK2, CALR or MPL and BCR::ABL1. | 0 |
| 37871900 | 2024 | IGJ and SPATS2L immunohistochemistry sensitively and specifically identify BCR::ABL1+ and BCR::ABL1-like B-acute lymphoblastic leukaemia. | 0 |
| 32871588 | 2021 | Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia. | 0 |
| 35296447 | 2022 | The Clinical Significance of BCR-ABL1 Mutations in Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Cell Transplantation. | 0 |
| 28437552 | 2017 | BCR-ABL1 transcript types showed distinct laboratory characteristics in patients with chronic myeloid leukemia. | 0 |
| 22118744 | 2011 | Chronic myeloid leukemia: current perspectives. | 0 |
Article Bibliography
| Pubmed ID | Last Year | Title | Authors |
|---|---|---|---|
| 11921274 | 2002 | Rare recurring balanced chromosome abnormalities in therapy-related myelodysplastic syndromes and acute leukemia: report from an international workshop. | Block AW et al |
Summary
Fusion gene
BCR/ABL1 BCR (22q11.23) ABL1 (9q34.12) COF 1739 1740 1741 1742 1743 1744 1745 1746 1747 1748 1751 1752 1753 1754 1755 1756 1757 1758 1759 1760 1761 1762 1763 1764 1765 1766 1768 1769 1771 1773 1774 1775 1777 1778 1779 1780 1781 1782 1783 1788 1789 1791 1793 1794|BCR/ABL1 BCR (22q11.23) ABL1 (9q34.12) FC FUSC001404|BCR/ABL1 BCR (22q11.23) ABL1 (9q34.12) M +der(22)t(9;22)(q34;q11) der(9)del(9)(q34q34)t(9;22)(q34;q11) der(9)ins(9;9)(q?;q34)t(9;22)(q34;q11) der(9)t(9;22)(q34;q11) ins(22;9)(q11;q34q21) ins(22;9)(q11;q34q34) ins(9;22)(q34;q11q11) t(10;9;22)(q25;q34;q11) t(11;9;22)(q12;q34;q11) t(1;9;22)(p34;q34;q11) t(1;9;22)(p35;q34;q11) t(1;9;22)(p36;q34;q11) t(1;9;22)(q21;q34;q11) t(1;9;22)(q24;q34;q11) t(1;9;22)(q32;q34;q11) t(1;9;22)(q42;q34;q11) t(2;9;22)(p13;q34;q11) t(2;9;22)(p21;q34;q11) t(2;9;22)(q11;q34;q11) t(2;9;22)(q37;q34;q11) t(3;22)(p24;q11) t(3;9;22)(p11;q34;q11) t(3;9;22)(p14;q34;q11) t(3;9;22)(p21;q34;q11) t(3;9;22)(p22;q34;q11) t(3;9;22)(p24;q34;q11) t(3;9;22)(p25;q34;q11) t(3;9;22)(q12;q34;q11) t(3;9;22)(q21;q34;q11) t(3;9;22)(q25;q34;q11) t(3;9;22)(q26;q34;q11) t(3;9;22)(q27;q34;q11) t(4;9;22)(p11;q34;q11) t(4;9;22)(p14;q34;q11) t(4;9;22)(p16;q34;q11) t(4;9;22)(q12;q34;q11) t(4;9;22)(q13;q34;q11) t(4;9;22)(q21;q34;q11) t(4;9;22)(q25;q34;q11) t(4;9;22)(q27;q34;q11) t(4;9;22)(q31;q34;q11) t(4;9;22)(q34;q34;q11) t(5;9;22)(p13;q34;q11) t(5;9;22)(p15;q34;q11) t(5;9;22)(q13;q34;q11) t(5;9;22)(q23;q34;q11) t(5;9;22)(q31;q34;q11) t(6;9;22)(p11;q34;q11) t(6;9;22)(p21;q34;q11) t(6;9;22)(p22;q34;q11) t(6;9;22)(p23;q34;q11) t(6;9;22)(p24;q34;q11) t(6;9;22)(p25;q34;q11) t(6;9;22)(q12;q34;q11) t(6;9;22)(q21;q34;q11) t(6;9;22)(q22;q34;q11) t(7;9;22)(p12;q34;q11) t(7;9;22)(p22;q34;q11) t(7;9;22)(q11;q34;q11) t(7;9;22)(q12;q34;q11) t(7;9;22)(q22;q34;q11) t(7;9;22)(q32;q34;q11) t(7;9;22)(q35;q34;q11) t(8;22)(q24;q11) t(8;9;22)(p11;q34;q11) t(8;9;22)(p12;q34;q11) t(8;9;22)(p23;q34;q11) t(8;9;22)(q21;q34;q11) t(8;9;22)(q22;q34;q11) t(9;10;22)(q34;q24;q11) t(9;11;22)(q34;p15;q11) t(9;11;22)(q34;q12;q11) t(9;11;22)(q34;q13;q11) t(9;12;22)(q34;p11;q11) t(9;12;22)(q34;p13;q11) t(9;12;22)(q34;q13;q11) t(9;12;22)(q34;q15;q11) t(9;13;22)(q34;q13;q11) t(9;13;22)(q34;q14;q11) t(9;13;22)(q34;q31;q11) t(9;14;22)(q34;q11;q11) t(9;14;22)(q34;q32;q11) t(9;15;22)(q34;q24;q11) t(9;17;22)(q34;q11;q11) t(9;17;22)(q34;q22;q11) t(9;17;22)(q34;q23;q11) t(9;19;22)(q34;q13;q11) t(9;21;22)(q34;q22;q11) t(9;22)(q34;q11) t(9;22)(q34;q11)t(9;9)(q13;q34)t(9;22) t(9;22;10)(q34;q11;p12) t(9;22;10)(q34;q11;p14) t(9;22;10)(q34;q11;q11) t(9;22;10)(q34;q11;q21) t(9;22;10)(q34;q11;q22) t(9;22;11)(q34;q11;p14) t(9;22;11)(q34;q11;q11) t(9;22;11)(q34;q11;q12) t(9;22;11)(q34;q11;q13) t(9;22;12)(q34;q11;p12) t(9;22;12)(q34;q11;p13) t(9;22;12)(q34;q11;q11) t(9;22;12)(q34;q11;q13) t(9;22;12)(q34;q11;q14) t(9;22;12)(q34;q11;q15) t(9;22;12)(q34;q11;q24) t(9;22;13)(q34;q11;p12) t(9;22;13)(q34;q11;q12) t(9;22;13)(q34;q11;q13) t(9;22;13)(q34;q11;q14) t(9;22;13)(q34;q11;q21) t(9;22;14)(q34;q11;p11) t(9;22;14)(q34;q11;q13) t(9;22;14)(q34;q11;q22) t(9;22;14)(q34;q11;q23) t(9;22;14)(q34;q11;q24) t(9;22;14)(q34;q11;q32) t(9;22;15)(q34;q11;q11) t(9;22;15)(q34;q11;q14) t(9;22;15)(q34;q11;q15) t(9;22;15)(q34;q11;q21) t(9;22;15)(q34;q11;q22) t(9;22;15)(q34;q11;q24) t(9;22;15)(q34;q11;q25) t(9;22;15)(q34;q11;q26) t(9;22;16)(q34;q11;p12) t(9;22;16)(q34;q11;p13) t(9;22;16)(q34;q11;q13) t(9;22;16)(q34;q11;q24) t(9;22;17)(q34;q11;p11) t(9;22;17)(q34;q11;p13) t(9;22;17)(q34;q11;q21) t(9;22;17)(q34;q11;q22) t(9;22;17)(q34;q11;q23) t(9;22;17)(q34;q11;q24) t(9;22;17)(q34;q11;q25) t(9;22;18)(q34;q11;p11) t(9;22;19)(q34;q11;p13) t(9;22;19)(q34;q11;q12) t(9;22;19)(q34;q11;q13) t(9;22;20)(q34;q11;p13) t(9;22;20)(q34;q11;q11) t(9;22;20)(q34;q11;q13) t(9;22;21)(q34;q11;p11) t(9;22;21)(q34;q11;q11) t(9;22;21)(q34;q11;q22) t(9;22;22)(q34;q11;q11) t(9;22;22)(q34;q11;q13) t(9;7;22)(q34;p21;q11) t(9;9;22)(p13;q34;q11) t(9;9;22)(p13;q34;q22) t(9;9;22)(q22;q34;q11) t(9;9;22)(q34;q34;q11) t(X;9;22)(p11;q34;q11) t(X;9;22)(p22;q34;q11) t(X;9;22)(q11;q34;q11) t(X;9;22)(q24;q34;q11) t(Y;9;22)(q12;q34;q11)|BCR/ABL1 BCR (22q11.23) ABL1 (9q34.12) TIC
Note
This data is extracted from a very large study from an International Workshop on treatment related leukemias - restricted to balanced chromosome aberrations (i.e.: -5/del(5q)and -7/del(7q) not taken into account per see), published in Genes,Chromosomes and Cancer in 2002.
t(9;22)(q34;q11) BCR/ABL1 Partial karyotypes with t(9;22)(q34;q11). Fluorescence in situ hybridization with the Vysis LSI BCR/ABL1 dual color dual fusion probes (Abbott Molecular, US) showing 2 copies of genes on normal (A) and fusion red-green signals on der(9) and der(22) chromosomes, the most frequently encountered FISH pattern in patients with t(9;22)(q34;q11) (B). In a smaller subset of patients a supernumerary Ph may be observed, as an extra der(22) chromosome (C) or it is resent in hyperdiploid karyotypes (D). Atypical fusion patterns include the presence of cryptic fusion signal (E), 1 fusion signal on der(22) chromosome (F), that may be with loss of residual proximal 9q (G). Sporadic variations may include the presence of derivative 9 and 22 chromosomes that result from the formation of isodicentric (H) or isochromosomes with or without 9q deletion (I,J) u2013 Courtesy Adriana Zamecnikova.
Citation
Jean-Loup Huret
t(9;22)(q34;q11) BCR/ABL1 in treatment related leukemia
Atlas Genet Cytogenet Oncol Haematol. 2003-10-01
Online version: http://atlasgeneticsoncology.org/haematological/1300/t(9;22)(q34;q11)-bcr-abl1-in-treatment-related-leukemia
